Ignite Creation Date:
2024-05-05 @ 6:35 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00503698
Status:
TERMINATED
Last Update Posted:
2017-03-07
First Post:
2007-07-18
Brief Title:
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Efficacy and Safety of Somatropin in Adult Patients on Chronic Haemodialysis
Status:
TERMINATED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
See termination reason in detailed description
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPPORTUNITY
Brief Summary:
This trial is conducted in Africa Asia Europe North and South America and Oceania
The aim of the trial is to evaluate the effect of somatropin human growth hormone on survival primary end-point time to death and health related quality of life in adult patients on chronic haemodialysis
The aim of the trial is to evaluate the effect of somatropin human growth hormone on survival primary end-point time to death and health related quality of life in adult patients on chronic haemodialysis
Detailed Description:
The decision to discontinue the trial is not due to safety concerns The discontinuation is based on an analysis of the significant delay in recruitment of patients which is expected to have a negative impact on the outcome of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-004702-56 | EUDRACT_NUMBER | None | None |